2024
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisorders
2022
Ghrelin Predicts Stimulant and Sedative Effects of Alcohol in Heavy Drinkers
Ralevski E, Horvath T, Shanabrough M, Newcomb J, Pisani E, Petrakis I. Ghrelin Predicts Stimulant and Sedative Effects of Alcohol in Heavy Drinkers. Alcohol And Alcoholism 2022, 58: 100-106. PMID: 36382470, PMCID: PMC9830489, DOI: 10.1093/alcalc/agac058.Peer-Reviewed Original Research